Wilson Sonsini Goodrich & Rosati advised eGenesis on the transaction. eGenesis, a biotechnology company developing human-compatible engineered organs to address the global organ shortage, announced the...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Marengo Therapeutics on the transaction. Marengo Therapeutics announced the expansion of their ongoing oncology research partnership to include TriSTAR, Marengo’s...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Verve on IP matters related to the transaction. Verve Therapeutics, Inc., a clinical-stage genetic medicines company, announced an exclusive research collaboration...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised Chroma Medicine on the deal. Genomic medicine company Chroma Medicine announced that it had completed a $135 million Series B financing, which was...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Marengo on the deal. Ipsen and Marengo Therapeutics announced a strategic partnership to advance two of Marengo’s preclinical STAR platform-generated...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Verve Therapeutics on the deal. Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised NAPIGEN on the deal. NAPIGEN, a company developing proprietary technology to edit mitochondrial and chloroplast genomes, announced the completion of $7.85 million seed...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised CellPoint on the deal. Walder Wyss has advised +ND Capital, while Baker McKenzie advised CellPoint and AboundBio. Galapagos, a fully...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Chroma Medicine on the deal. Chroma Medicine, a new genomic medicine company pioneering epigenetic editing, launched with $125 million in...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Verve Therapeutics on the deal. Verve Therapeutics (Nasdaq: VERV), a biotech company pioneering a new approach to the care of...
You must be a Standard 1 Year member to access this content.
